期刊
ADVANCED FUNCTIONAL MATERIALS
卷 31, 期 12, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adfm.202008061
关键词
immunogenic cell death; immunotherapy; nanomedicine; photodynamic therapy; sonodynamic therapy
类别
资金
- Korea Research Fellowship (KRF) Program of the National Research Foundation (NRF), Republic of Korea [2019H1D3A1A01071101]
- Basic Science Research Programs of the National Research Foundation (NRF), Republic of Korea [2019R1I1A1A01061426, 2018R1A2B3006080]
- National Natural Science Foundation of China [51703074, 51525302]
- China Postdoctoral Science Foundation [2017M612454]
- National Research Foundation of Korea [2019H1D3A1A01071101, 2018R1A2B3006080, 2019R1I1A1A01061426] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Immunotherapy is a potent cancer therapy but its clinical applications are limited by low response rates and immune-related adverse effects. Sono/photodynamic nanomedicines (SPNs) have gained attention for enhancing immunotherapy by generating reactive oxygen species and promoting immunogenic cancer cell death.
Immunotherapy (e.g., cancer vaccines and checkpoint blockades), harnessing the host immune system to recognize and eradicate tumors, has emerged as one of the most potent cancer therapies. The clinical applications of cancer immunotherapies, however, have been limited by their low response rates and immune-related adverse effects. In recent years, sono/photodynamic nanomedicines (SPNs) have received increasing attention for cancer therapy since they have been reported to mediate enhanced immunotherapy by generating reactive oxygen species under site-specific exposure to exogenous energy sources. In particular, SPNs are capable of eliciting immunogenic cancer cell death, leading to the release of tumor-associated antigens and damage-associated molecular patterns. This allows for the maturation of antigen-presenting cells, thus eliminating disseminated or metastatic tumor cells by cytotoxic CD8(+) T cells. Such immunostimulatory features of SPNs provide opportunities to enhance therapeutic potential by amplifying anticancer immunity when combined with conventional immunotherapeutics, including immune checkpoint inhibitors. This review elaborates on the recent strategies and efforts undertaken by researchers to enhance SPN-elicited cancer immunotherapy. The challenging issues and opportunities for SPNs in the activation of innate or adaptive immune responses and regulation of the tumor immunosuppressive microenvironment are also described.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据